GcMAF is administered by a simple intramuscular (IM) or subcutaneous (SC) injection. It is given 1-2 times per week or as directed by your physician.
Experiments showed that injected GcMAF-RF activated murine macrophages, resulting in a polarization towards the antitumor M1 phenotype. It also increased phagocytosis and the production of nitric oxide.
Anti-tumor
GcMAF yogurt activates macrophages, which are important phagocytic cells that can infiltrate tumors. Studies show that gcmaf-primed macrophages can kill cancerous cells in the laboratory. They can also stop the growth of new blood vessels and inhibit migration. This anti-tumor effect is especially pronounced in undifferentiated cancers. Several studies have claimed that gcmaf can wipe out breast, colorectal, and prostate cancers. However, these claims have been criticized because of the small number of patients studied and the poor research methods used.
A study by Yamamoto et al showed that GcMAF therapy reduced PSA levels in 16 patients with advanced prostate cancer. In addition, they observed that patients who had GcMAF treatment along with hyper-T/NK cell and high-dose vitamin C therapy achieved longer-term remissions (36).
Saisei Mirai’s second-generation gcmaf is more stable than first-generation GcMAF and has increased phagocytic activity, superoxide production, and anti-angiogenic effects. It is produced under aseptic conditions in a specialized facility and sterile filtered. 0.5ml of our GcMAF contains approximately 1500ng of active GcMAF. This is an approximate value since GcMAF concentration varies between serum samples, similar to natural killer cells and lymphocytes.
Anti-viral
Gc MAF naturally occurs in the human body and activates macrophages to destroy cancer cells, foreign viruses and bacteria. It also destroys viruses that cause serious illnesses like HIV, viral hepatitis and influenza. Second-generation GcMAF is produced in our sterile Saisei Mirai Cell Processing Center (CPC) from healthy serum that has been carefully screened and the final product sterile filtered to ensure safety. It is then injected intramuscularly. The phagocytic activity of the second-generation GcMAF is demonstrated by the purple color that is seen on opsonized red blood cells that are ingested by macrophages activated with Gc MAF.
In 2008/2009 four papers appeared from the research of Nobutu Yamamoto (Philadelphia) describing successful immunotherapy of patients with a wide variety of cancers and pathogenic envelope viruses such as HIV-1 using a mammalian protein called GcMAF that has an incredible potency to directly activate macrophages. In these studies Yamamoto monitored the progress of his immunotherapy by measuring the serum level of nagalase (a-N-acetylgalactosaminidase activity at pH 6). Yamamoto’s results were spectacular and his approach to immune therapy seemed almost too good to be true.
Anti-inflammatory
In addition to the anti-tumor effects of GcMAF, it also has significant anti-inflammatory properties. Studies have shown that when GcMAF is injected into the tumor microenvironment, it stimulates M2 macrophages to adopt M1 macrophage functions. This reprogramming results in the death of cancer cells, thereby suppressing tumor growth.
The anti-inflammatory activity of gcmaf is also attributed to its ability to release tumor cell membrane lipid metabolites, including alkylglycerols and lyso-alkylphospholipids. These lipids can cause cancer cells to die by causing oxidative stress and inhibiting the growth of new cancer cells.
Several clinical cases of successful use of second-generation GcMAF on compassionate basis in advanced cancer patients have been reported. These patients received high doses of second-generation GcMAF and complementary therapies such as sonodynamic therapy. In one case, a 55-year-old woman with breast cancer experienced complete regression of a right axillary tumor, spinal metastasis and intrapleural nodular tumor and right pleural effusion. She received a series of high-dose intramuscular injections of second-generation GcMAF for a period of less than a year with no apparent side effects.
Immunomodulatory
GcMAF is a natural protein that stimulates macrophages to attack and destroy cancer cells. It has been shown to be effective against a variety of tumors and is also effective in preventing recurrence of the disease. It has also been reported to have anti-angiogenesis and immunomodulatory properties.
Inflamed tissues release cell membrane lipid metabolites that activate macrophages to bind and kill neoplastic cells. Activated macrophages secrete toxic lysophosphatidylcholine that destroys the neoplastic cells and prevents them from growing and spreading throughout the body.
The first-generation gcMAF developed by Saisei Mirai has been found to increase the phagocytosis of monocytes and other immune cells. It also increases the maturation of dendritic cells. It has been used in over 1,000 patients, primarily in combination with sonodynamic photodynamic therapy (SDT). This new generation of gcMAF has more stability and higher concentrations than the first-generation product. It is also less likely to interact with antibodies. This allows it to be safely used in conjunction with conventional therapies.